# Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Im

Source: https://onco.cc/trials/nct06486441/  
OnCo record `nct06486441` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Sacituzumab govitecan, Doxorubicin, Paclitaxel / nab-paclitaxel in endometrial cancer, run by Gilead Sciences, active and no longer recruiting.

## Summary

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26) is a phase 3 interventional study registered as NCT06486441 by Gilead Sciences, with 640 participants planned, started 2024-08-28 and due to reach its primary completion in 2029-06. Interventions recorded: Sacituzumab govitecan-hziy, Doxorubicin, Paclitaxel. Conditions listed: Endometrial Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06486441
- Phase: 3
- Setting: A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy
- Sponsor: Gilead Sciences
- Enrolled: 640

## Sources

- ClinicalTrials.gov NCT06486441: https://clinicaltrials.gov/study/NCT06486441

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/)
- drugs: [Doxorubicin](https://onco.cc/drugs/doxorubicin/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Sacituzumab govitecan](https://onco.cc/drugs/sacituzumab-govitecan/)
- companies: [Gilead Sciences (incl. Kite)](https://onco.cc/companies/gilead/)

---
JSON: https://onco.cc/api/v1/entities/nct06486441.json